1,5-diethyl 2-propanoylpentanedioate | 70556-93-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: 1,5-diethyl 2-propanoylpentanedioate
• 英文别名: diethyl 2-propionylglutarate；2-propionyl-glutaric acid diethyl ester；2-Propionyl-glutarsaeure-diaethylester；Diethyl 2-propanoylpentanedioate；diethyl 2-propanoylpentanedioate
• CAS: 70556-93-3
• 化学式: C₁₂H₂₀O₅
• 分子量: 244.288
• InChiKey: GHOWWQHQQKLPFO-UHFFFAOYSA-N

物化性质

• 沸点：
  316.5±22.0 °C(Predicted)
• 密度：
  1.057±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  69.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1,5-diethyl 2-propanoylpentanedioate 在 氯仿 、 溴 作用下， 生成 3-(5-methyl-2,4-dioxo-tetrahydro-[3]furyl)-propionic acid ethyl ester
  参考文献：
  名称：

  Reuter; Welch, Journal and Proceedings - Royal Society of New South Wales, 1938, vol. 72, p. 124

  摘要：

  DOI：
• 作为产物：
  描述：

  丙烯酸乙酯 、 丙酰乙酸乙酯 在 sodium methylate 、 苄基三甲基溴化铵 作用下， 以 正己烷 为溶剂， 反应 6.33h， 以93%的产率得到1,5-diethyl 2-propanoylpentanedioate
  参考文献：
  名称：

  一种含多官能团结构的高pH值铬鞣助剂及其制备方法与应用

  摘要：

  本发明公开了一种含多官能团结构的高pH值铬鞣助剂及其制备方法与应用，该助剂结构为含酮羧酸酯的多官能团化合物；本发明公开了一种高pH值铬鞣助剂的制备方法及高pH值铬鞣应用工艺；本发明的铬鞣助剂结构中含有酮羰基和羧酸酯结构，在碱性条件下与胶原蛋白中的精氨酸反应，实现胶原改性；羧酸酯水解产生羧基(‑COOH)，增加胶原侧链羧基数量，增加与三价铬配位位点，实现铬鞣剂的高吸收，减少铬鞣废水中三价铬的浓度，减少制革工业的环境污染，推进制革产业清洁化生产；本发明操作简单，为高pH值铬鞣助剂的研究提供了一种新思路。

  公开号：

  CN112778133B

文献信息

• [EN] NON-PEPTIDIC HETEROCYCLE-CONTAINING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] COMPOSÉS NON PÉPTIDIQUES CONTENANT DES HÉTÉROCYCLES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：UNIV ALBERTA

  公开号：WO2020215157A1

  公开（公告）日：2020-10-29

  The present disclosure provides non-peptidic heterocycle-containing amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the amylin receptor antagonists for treating, preventing, or ameliorating Alzheimer's disease. Aspects of the present disclosure include a method of inhibiting activity of an amylin receptor by administering to a subject in need thereof a therapeutically effective amount of an amylin receptor antagonist.

  本公开提供了含非肽杂环的胰岛素类受体拮抗剂化合物，包括该类化合物的组合物，用于制备和使用胰岛素类受体拮抗剂的方法，以及含有胰岛素类受体拮抗剂的组合物，用于治疗、预防或改善阿尔茨海默病。本公开的方面包括通过向需要的受试者投与治疗有效量的胰岛素类受体拮抗剂来抑制胰岛素类受体活性的方法。
• IRE-1alpha INHIBITORS
  申请人：MannKind Corporation

  公开号：US20150141424A1

  公开（公告）日：2015-05-21

  Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

  在体外直接抑制IRE-1α活性的化合物、前药及其药学上可接受的盐。这些化合物和前药可用于治疗与未折叠蛋白应答或受调节的IRE1依赖性降解（RIDD）相关的疾病，并可作为单一药物或联合治疗的组合疗法。
• Franke; Kroupa, Monatshefte fur Chemie, 1936, vol. 69, p. 190
  作者：Franke、Kroupa

  DOI：——

  日期：——
• Pyrido[2,3-d]pyrimidine Angiotensin II Antagonists
  作者：John W. Ellingboe、Madelene Antane、Thomas T. Nguyen、Michael D. Collini、Schuyler Antane、Reinhold Bender、Dale Hartupee、Valerie White、John McCallum

  DOI：10.1021/jm00030a013

  日期：1994.2

  A series of pyrido[2,3-d]pyrimidine angiotensin II (A II) antagonists was synthesized and tested for antagonism of A II. Compounds with a biphenylyltetrazole pharmacophore and small alkyl groups at the 2- and ii-positions Of the pyridopyrimidine ring were found to be the most potent in an AT(1) receptor binding assay and in blocking the A II presser response in anesthetized, ganglion-blocked A II-infused rats. 5,8-Dihydro-2,4-dimethyl-8-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl] pyrido[2,3-d]pyrimidin-7(6H)-one (4a) was one of the more potent compounds in the binding assay and was the most efficacious compound in the A II-infused rat model. Further study of 4a;in Goldblatt (2K-1C) rats showed the compound to have oral bioavailability and to be an efficacious and potent compound in a high renin form of hypertension.
• IRE-1ALPHA INHIBITORS
  申请人：Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

  公开号：US20170326104A1

  公开（公告）日：2017-11-16

  Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.